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Abstract
Ovarian cancer is among the most lethal of all malignancies in women. While chemotherapy is the
preferred treatment modality, chemoresistance severely limits treatment success. Recent evidence
suggests that deregulation of key pro- and anti-apoptotic pathways is a key factor in the onset and
maintenance of chemoresistance. Furthermore, the discovery of novel interactions between these
pathways suggests that chemoresistance may be multi-factorial. Ultimately, the decision of the
cancer cell to live or die in response to a chemotherapeutic agent is a consequence of the overall
apoptotic capacity of that cell. In this review, we discuss the biochemical pathways believed to
promote cell survival and how they modulate chemosensitivity. We then conclude with some new
research directions by which the fundamental mechanisms of chemoresistance can be elucidated.
Ovarian Cancer and Chemoresistance: A 
Molecular and Cellular Perspective
Although ovarian cancer ranks seventh among all cancers
in women in terms of prevalence, almost 60% of those
who have ovarian cancer eventually succumb to the dis-
ease. In 2002, 23,300 new cases were identified and
13,900 deaths were reported in the United States alone.
While breast cancer has a much higher incidence
(203,500 new cases), it has a considerably lower mortality
rate (39,600 deaths; approximately 20% mortality rate)
when compared to that of ovarian cancer [1]. In fact, ovar-
ian cancer causes more deaths than any other cancer of the
female reproductive system. Much of the failure to obtain
better cure rates in ovarian cancer is a consequence of late
diagnosis; only about 25% of patients are diagnosed
when the disease is still confined to the ovary. At
advanced stages (stages III and IV), when the disease has
spread beyond the ovary, treatment becomes increasingly
ineffective.
Currently, the preferred treatment regimen for ovarian
cancer is combination chemotherapy; usually a platinum-
based drug, such as cisplatin or carboplatin, coupled with
paclitaxel. While this treatment course shows promising
effects in a high percentage of cases, the development of
chemoresistance is a hurdle that significantly hinders suc-
cessful treatment outcomes [2]. The ability of a cancer cell
to respond to a chemotherapeutic agent is believed to be
due, in part, to its apoptotic capacity. Moreover, it is
accepted that the process of drug-induced apoptosis is
governed not only by the upregulation of pro-apoptotic
factors or tumor suppressors, but also by modulation of
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cell survival factors. To that end, a number of genes
involved in either the induction or inhibition of apopto-
sis, namely the p53, Akt, and phosphoinositol-3-OH-
kinase (PI3K) gene families, are aberrantly regulated in
ovarian cancer [3,4]. Because of their wide-ranging bio-
logical effects, deregulation of one or more of these factors
may give rise to a failure of drug-induced apoptosis.
As such, a number of groups have focused their research
on elucidating the precise mechanisms by which chemo-
therapeutic agents induce, and by extension fail to induce,
apoptosis in ovarian cancer cells. We and others have
been particularly focused on elucidating the mechanisms
by which several key apoptotic regulators, including p53,
the Inhibitor of Apoptosis (IAP) family, the Akt family,
and the death-receptor family, may influence the response
of ovarian cancer cells to cisplatin. We have found that
aberrant regulation of these pathways plays a significant
role in the induction and maintenance of chemoresist-
ance. This review first outlines some of the major regula-
tory pathways implicated in control of cell fate. We then
elucidate some of the recently established interactions
between these apoptotic regulators, and show how these
interactions are critical for chemoresistance. Finally, we
explore some potential avenues for future work in this
area.
The effectiveness of many of the chemotherapeutic agents
used in human cancer is highly dependent upon the abil-
ity of the cancer cell to undergo drug-induced apoptosis.
It is now widely held that the decision to live or die in
response to a given agent is a reflection of the overall
apoptotic balance within a given cell. For example, cispla-
tin has been shown to upregulate the pro-apoptotic fac-
tors p53, Fas, and Bax in a number of cell types [5–7].
However, it also down-regulates specific cell survival fac-
tors such as Xiap and Akt [8]. Recent evidence suggests
that chemoresistance may represent an overall imbalance
between these two phenomena. To that end, we and oth-
ers have long been interested in elucidating the mecha-
nisms of action of cisplatin in terms of its ability to
influence these cell survival and death pathways. These
studies have identified a number of signaling pathways
that are differentially regulated between chemosensitive
and chemoresistant ovarian cancer cells. We will outline
some of these pathways, and their potential cross-talk
hereafter.
Cell survival factors
While apoptosis is an important mechanism in normal
development and prevention of abnormal cell growth,
certain cellular survival factors are required to prevent
inappropriate cell death. In an effort to elucidate the cel-
lular mechanisms of chemoresistance in ovarian cancer, a
number of novel cell survival proteins have been exam-
ined as potential determinants of chemosensitivity. Sev-
eral such proteins are outlined below.
X-linked inhibitor of apoptosis protein
IAPs were first identified in baculovirus and the eukaryo-
tic homologues were subsequently characterized [9]. Cur-
rently, the human IAP family includes X-linked inhibitor
of apoptosis protein (Xiap), human inhibitor of apoptosis
protein (Hiap) -1 and -2, neuronal apoptosis inhibitor
protein (Naip), survivin and livin [10]. All IAPs contain
one or more baculovirus inhibitor of apoptosis repeat
(BIR) domains that block the substrate binding sites of
target caspases (Figure 1). Xiap is a 55 kDa protein, which
contains three BIR domains at the N-terminus. It requires
no proteolytic processing for full function and has been
shown to have high affinity for caspases. Xiap directly
inhibits the initiator caspase-9 and execution caspase-3
and -7. Thus, Xiap attenuates both mitochondria/cyto-
chrome c- and death receptor-mediated apoptosis [11].
Moreover, Xiap contains a C-terminus RING-Zinc finger
domain with E3 ubiquitin ligase activity [12], which is
believed to be involved in caspase degradation via the 26S
proteasome. In addition, Xiap can undergo autoubiquiti-
nation, and Lys322 and Lys328 have recently been dem-
onstrated to be the specific sites of ubiquitin ligation to
Xiap [13]. However, the effects of Xiap autoubiquitination
on its overall function remain unclear. In addition, the
Xiap mRNA contains an Internal Ribosomal Entry Site
(IRES) element [14], which allows Xiap to be translated in
a cap-independent manner during cellular stress. In con-
trast, non-IRES containing mRNAs are translated exclu-
sively in a 5' cap-dependent manner, a process that is
often suspended during apoptosis due to the cleavage of
transcription initiation factor 4G (eIF4G) by caspase 3.
Recently, several cellular factors have been shown to bind
Xiap and inhibit its activity, including Xiap Associated
Factor 1 (XAF-1), Htr2A/Omi and Second Mitochondrial
Activator of Caspases (Smac or DIABLO) [15–17]. It has
been demonstrated that Smac is released from the mito-
chondria during dexamethasone-induced apoptosis in
multiple myeloma cells [18], further supporting the role
of Xiap as a central molecule in cell survival.
We previously reported that cisplatin down-regulates Xiap
in chemosensitive, but not chemoresistant, ovarian cancer
cells [8]. Moreover, Xiap is a determinant of chemoresist-
ance, since downregulation of Xiap in chemoresistant
cells rendered the cells sensitive to the cytotoxic actions of
cisplatin, while overexpression of Xiap in chemosensitive
cells caused a reversion to the chemoresistant phenotype
[8,19].Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66
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FLICE-like inhibitory protein confers TNFα 
resistance on ovarian cancer cells
Death receptors (DRs) are cell surface proteins belonging
to the tumor necrosis factor (TNF) super-family. Recent
studies suggest that these receptors or their downstream
effectors play important role in regulating apoptosis, cel-
lular growth and proliferation. The most widely studied
DRs are Fas (also known as CD95), TNF receptor-1 and -
2 (TNFR1 and TNFR2, respectively), and the TNF-related
apoptosis inducing ligand (TRAIL) receptors, all of which
are characterized by 1) cysteine-rich extracellular sub-
domains and 2) an intracellular region of about 80 amino
The Inhibitor of Apoptosis Proteins Figure 1
The Inhibitor of Apoptosis Proteins The human Inhibitor of Apoptosis Protein (IAP) family, originally characterized in bac-
ulovirus, currently consists of 6 members: X-Linked Inhibitor of Apoptosis Protein (Xiap), Human Inhibitor of Apoptosis Pro-
tein-1 and -2 (Hiap-1, -2), Neuronal Apoptosis Inhibitory Protein (Naip), survivin, and livin. Xiap is a 498-amino acid (~55 kDa) 
protein and is a potent inhibitor of caspases, including caspase-9, -7, and -3. Xiap contains three Baculoviral Inhibitory Repeat 
(BIR) domains, which are involved in direct inhibition of target caspases. Furthermore, Xiap contains a C-terminal RING-Zn 
Finger domain, which contains E3 Ubiquitin Ligase activity. In this regard, Xiap is known to ubiquitinate several target proteins, 
including caspase-3 and Smac/DIABLO. Xiap is also known to undergo autoubiqutination on Lys322 and Lys328. The role of 
Xiap's E3 activity in the regulation of apoptosis is unclear. Finally, Xiap is itself cleaved in a caspase-dependent manner during 
Fas-induced apoptosis. This cleavage occurs at the SESD sequence (amino acids 239–242), located between BIR domains 2 and 
3, and results in the production of 2 ~30 kDa fragments of unknown function. Recent data from our laboratory suggests that 
Xiap is a determinant of cisplatin-mediated chemoresistance, and that the anti-apoptotic effects of Xiap are in part due to 
upregulation of the PI3K/Akt pathway and to suppression of p53-mediated cell death.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66
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acids, termed the death domain (DD). The cysteine-rich
extracellular subdomains are thought to adopt tertiary
folds, required for intracellular clustering of DD motifs.
The DD motif is essential for the transmission of cytotoxic
signals and the induction of apoptotic cell death via
recruitment of adapter proteins also containing a DD
motif [e.g. Fas-associated death domain (FADD), TNFR-
associated death domain (TRADD)] and formation of a
receptor signaling complex [20].
Initiator caspases implicated in the DR-mediated apop-
totic pathways (e.g. Caspase-8) are activated through
interaction with the caspase-recruitment domain (CARD)
motif of the DR-associating proteins [21]. Downstream
execution caspases (e.g. caspase-3 and 7) are subsequently
activated by initiator caspases. Two of the death receptor
pathways, TNFα-TNFR1 and FasL-Fas, have been sug-
gested to play an important role in chemoresistance in
ovarian cancer cells.
Fas Ligand (FasL), a homotrimeric membrane protein,
binds three Fas receptor molecules on the surface of the
target cell, resulting in intracellular clustering of DDs and
the recruitment of FADD to the receptor via homologous
DD interactions [22]. The Fas-FADD complex recruits
inactive caspase-8 (also called FLICE) by a homophilic
interaction involving the death effector domains (DED)
of FADD and FLICE. Upon recruitment by FADD, the pro-
caspase-8 is cleaved to produce active caspase-8, which
triggers activation of caspase-3 or -7. In human ovarian
cancer cells, DNA damaging agents such as cisplatin can
up-regulate Fas and FasL, resulting in activation of cas-
pase-8 and -3 and induction of apoptosis [23]. We have
shown that cisplatin is effective in inducing the expression
of cell associated Fas and FasL, soluble FasL and apoptosis
in two cisplatin-sensitive cell lines in a concentration- and
time-dependent fashion [7]. In a chemoresistant variant,
cisplatin failed to up-regulate FasL or induce apoptosis.
Our results are supportive of the notion that dysregulation
of the Fas/FasL system maybe an important determinant
in cisplatin resistance in ovarian cancer cells.
Similar to the Fas/FasL pathway, binding of TNFα to
TNFR1 results in receptor trimerization, death domain
clustering, recruitment of TRADD and other proteins (e.g.
FADD), cleavage and activation of pro-caspase-8 and the
initiation of apoptosis. However, unlike the Fas-FasL sys-
tem, binding of TNFα to TNFR1 is not sufficient to initiate
apoptosis. Binding of TNFα to TNFR2 induces IκB phos-
phorylation and degradation and activates Nuclear Factor
κB (NFκB) [24,25], which in turn regulates TNFα-induced
apoptosis by inducing the expression of genes which
modulate apoptotic pathways (e.g. IAPs and FLIP).
Fas-associated death domain-like interleukin-1β-convert-
ing enzyme (FLICE)-like inhibitory protein (FLIP) is a
FADD-binding suppressor of apoptosis, which are present
in two alternately spliced isoforms: long (FLIPL) and short
(FLIPS) FLIP [26]. Both isoforms contain two death effec-
tor domains (DED), a structure resembling the N-termi-
nal half of caspase-8 [27,28]. FLIP is recruited to the
death-inducing signaling complex through FADD,
thereby preventing caspase-8 recruitment and activation,
and downstream apoptotic events [26,29] (see Figure 2).
We have recently demonstrated that TNFα induces NFκB-
mediated FLIPs expression, which protects ovarian cancer
cells from the cytotoxic action of the cytokine [30]. While
TNFα alone was unable to induce apoptosis, it effectively
induced apoptotic cell death in the presence of the protein
synthesis inhibitor cycloheximide. These effects could be
attenuated by sense FLIPs cDNA expression, suggesting
that the resistance of ovarian cancer cells to the cytotoxic
action of TNFα may be associated with the induction of
FLIPs in response to the cytokine [30]. It is of interest to
note that the role of FLIP in conferring resistance to cell
surface receptor-mediated apoptosis is not confined to the
actions of TNFα. TRAIL induces apoptosis in tumor cells
via activation of death receptors DR4 and DR5 [31] and
genotoxic agents (e.g. actinomycin D and ionizing radia-
tion) sensitize TRAIL-induced cytotoxicity by decreasing
intracellular levels of FLIP or increasing DR5 gene expres-
sion [32,33]. FLIPL also contributes to resistance to Fas-
mediated apoptosis in MF-63 cells, and sensitization to
Fas-mediated apoptosis by cisplatin [34]. In addition,
since activation of the Fas/FasL system is an important
mechanism of cisplatin-induced apoptosis in human
ovarian cancer cells [7], the possibililty that FLIP is differ-
entially regulated in chemoresistant ovarian cancer cells
cannot be excluded.
The PI3K/AKT Cell Survival Pathway
Phosphoinositide 3-Kinases (PI3Ks) are heterodimers
with separate regulatory (p85) and catalytic (p110) subu-
nits. PI3Ks are generally activated upon recruitment of the
inactive p85-p110 complex to receptor tyrosine kinases
(RTKs), by interaction of the Src-homology 2 (SH2)
domain of p85 with consensus phosphotyrosine residues
at the receptors, in response to an appropriate physiologic
cue (e.g. Growth factor stimulation) [35]. PI3K activation
may be due to: 1) the close proximity of p110 to its lipid
substrates in the membrane and 2) relief of the inhibitory
effect of p85 on p110 kinase activity upon RTK-p85 inter-
action [36]. Direct binding of p110 to activated Ras pro-
teins following growth factor stimulation further
stimulates PI3K activity [37]. Class Ia PI3Ks are primarily
involved in the phosphorylation of inositol-containing
lipids, phosphatidylinositols (PtdIns), at the 3'-position
of the inositol ring [38]. One of the reactions catalyzed byReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66
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PI3K is the conversion of PtdIns-4,5-bisphosphate (PIP2)
to PtdIns-3,4,5-trisphosphate (PIP3). Signaling proteins
with pleckstrin homology (PH) domains accumulate at
sites of PI3K activation by directly binding to PIP3. Of par-
ticular interest are AKT (a subfamily of the serine/threo-
nine protein kinases), and phosphoinositide-dependent
protein kinases (PDKs). Association of AKT and PDKs
with PIP3 facilitates phosphorylation and subsequent
activation of AKT by PDKs. Four sites (Ser124, Thr308,
Thr450, and Ser473) are phosphorylated on AKT in vivo
[39]. Whereas Ser124 and Thr450 appear to be phosphor-
ylated under basal conditions [40], the Thr308 and Ser473
Hypothetical Model of Chemoresistance in Human Ovarian Cancer Cells Figure 2
Hypothetical Model of Chemoresistance in Human Ovarian Cancer Cells. In a chemosensitive ovarian cancer cell 
(A), cisplatin increases p53 content, leading to upregulation of proteins promoting cell cycle arrest, such as p21, and of pro-
apoptotic proteins such as Bax and Fas. This activates both the intrinsic (mitochondrial) and extrinsic (death-receptor) apop-
totic pathways, the overall result of which is the activation of the execution caspase-3 (and -7, not shown). In these cells, cell 
survival mediators such as Xiap, Akt, and Flip (shown in red) are downregulated or are in their inactive state. Prohibitin may 
also play a role in inhibiting cell cycle progression through the Rb-E2F pathway by binding to Rb. Conversely, in a chemoresist-
ant cell (B), increased p53 ubiquitination by MDM2 results in the maintenance of low levels of p53, despite the presence of cis-
platin. Moreover, cisplatin fails to downregulate Xiap, thereby maintaining an active state of the PI3K/Akt pathway. In addition, 
binding of TNFR2 by TNFα leads to upregulation of FLIP through the NFκB pathway, thus inhibiting the pro-apoptotic actions 
of the cytokine through TNFR1. Overall, as a consequence of a failure to activate the caspase cascade in response to the chem-
otherapeutic agent, these cells have lost their capacity to undergo apoptosis, and thus became chemoresistant.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66
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residues are phosphorylated in response to a variety of
extracellular stimuli, and are required for AKT activity.
Three AKT isoforms (AKT1, AKT2, and AKT3) have been
identified, all of which share an N-terminal PH domain, a
central kinase domain, and a serine/threonine-rich C-ter-
minal region [40]. The overall homology among AKT1,
AKT2 and AKT3 is more than 85%. AKT is the only down-
stream target of PI3K that has been associated with malig-
nant transformation and its activation mediates a variety
of cellular responses including cell growth, transforma-
tion, differentiation, motility, and cell survival. The inter-
mediates of the PI3K/AKT survival pathway are often
altered in human ovarian cancer and high levels of PI3K
and AKTs have been linked to poor prognosis and chem-
oresistance [35]. Amplification of AKT2 has been demon-
strated in breast, ovarian and pancreatic cancer [41–44].
Moreover, the gene that encodes the p110 subunit of PI3K
is amplified in some cases of ovarian cancer, and the p85
subunit of PI3K is also targeted for mutation in human
cancer [45]. A truncated p65 PI3K subunit (isolated from
human tumor cell lines) causes constitutive activation of
PI3K and cell transformation [46]. Activating mutations
in the RTKs and loss of function of PTEN (phosphatase
and tensin homology; a lipid phosphatase that inhibits
PI3K/AKT signaling pathway by converting PIP3 to PIP2),
in a wide array of human cancers furthermore supports
the notion that PI3K/AKT pathway is involved in human
cancer [47].
Recent evidence has demonstrated a role for the PI3K/Akt
pathway in the resistance to a number of anti-tumor
agents. We and others have demonstrated that cells
expressing a constitutively active Akt2 are resistant to cis-
platin [48,49]. Furthermore, a recent report has demon-
strated that expression of a constitutively active PI3K
catalytic subunit renders ovarian carcinoma cells resistant
to paclitaxel, an effect that could be reversed by the PI3K
inhibitor, LY294002 [50]. In this study, nude mice carry-
ing ovarian cancer xenografts were treated with paclitaxel
and LY294002. While both agents significantly reduced
tumor burden alone (51 and 38%, respectively), they
acted synergistically and reduced tumor burden by 80%,
suggesting that inhibition of the PI3K/Akt pathway could
potentially act as a potent adjuvant to traditional
chemotherapies.
Focal Adhesion Kinase
Focal-Adhesion Kinase (FAK) is a 125 kDa, non-receptor
protein tyrosine kinase, which is autophosphorylated on
Tyr397 following association with integrin [51]. Activation
of FAK is associated with suppressed apoptosis, an effect
believed to result from activation of both the Ras/MAP
Kinase pathway and the PI3K/Akt pathway [52,53]. It has
been demonstrated that FAK suppresses detachment-
induced apoptosis, and that inhibition of FAK activates
caspases -3 and -8 and induces apoptosis [54]. Phosphor-
ylation of Tyr397 promotes the binding of a number of
SH2-containing proteins, including Src, PLCγ, Grb7, and
PI3K [55–57]. In addition, phosphorylation of several C-
terminal residues, including Tyr925, promotes the activa-
tion of the Ras/MAPK pathway through activation of Grb2
[58]. The N-terminal of FAK is believed play a role in
binding to the cytoplasmic tails of β integrin subunits
[59]. The co-localization of FAK with integrins in focal
adhesions appears to be necessary for cell adhesion-
dependent activation of FAK. Both the catalytic activity
and the major autophosphorylation site of FAK are
required for the anti-apoptotic effects of FAK [60]. One
recent study has demonstrated that the association of FAK
with PI3K is a prerequisite for the inhibition of UV-
induced apoptosis [61]. In addition, Tyr925, which is
implicated in the activation of the Ras/MAPK pathway, is
also an important residue in the FAK-mediated inhibition
of apoptosis [62]. Moreover, FAK overexpression
enhances NFκB activity and increases expression of several
members of the IAP family, including Xiap [63]. Finally,
FAK contains a caspase-3 consensus D-X-X-D sequence,
and has been shown to be a caspase-3 substrate [64],
although the functional consequences of FAK cleavage are
unclear. Nonetheless, FAK activity and stability appear to
be closely related to a number of cell fate regulators and
proper regulation of FAK appears to be required for the
correct determination of cell fate.
Prohibitin
The prohibitin gene was originally cloned based on its
ability to induce growth arrest at the G1/S phase of the cell
cycle in mammalian fibroblasts and HeLa cells. It is
located on human chromosome 17q21 close to the ovar-
ian and breast carcinoma susceptibility gene BRCA1 [65],
although no information currently exists on the role of
prohibitin gene products in ovarian tumor ontogeny. Pro-
hibitin mutations have been reported in a subset of spo-
radic breast cancers [65]. The prohibitin gene encodes a
protein of 275 amino acids that is evolutionarily con-
served in a wide variety of organisms. Prohibitin was
found to share substantial homology with a Drosophila
melanogaster gene product, Cc, of unknown function but
vital for normal development and differentiation [66].
Flies homozygous for non-functional Cc alleles die during
the larva to pupa metamorphosis. Within the parasitic
worm, Trypanosoma brucei, prohibitin is upregulated dur-
ing concanavalin A-induced apoptosis. The Trypanosoma
prohibitin homologue appears to contain a putative death
domain [67]. We have observed that prohibitin is up-reg-
ulated in normal ovarian cells undergoing apoptosis
induced by gonadotropin releasing hormone (GnRH)
agonist or gonadotropin withdrawal [68] and is primarily
associated with the mitochondria in the ovarian cells. TheReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66
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mechanism(s) by which prohibitin interacts with estab-
lished cell death pathways to regulate apoptosis is unclear.
Fusaro et al., (2002) demonstrated that stable over-expres-
sion of prohibitin in a human B cell line blocked apopto-
sis induced by the topoisomerase I inhibitor
camptothecin and showed a protective role of prohibitin
in breast cancer cell lines treated with the chemotherapeu-
tic agent, suggesting that this protein may be a cell survival
or anti-apoptotic factor, and plays an important role in
determining the chemosensitivity of the cells [69].
Whether a similar anti-apoptotic mechanism for prohibi-
tin is operational in the ovary remains to be determined.
This interpretation could also account for the accumula-
tion of prohibitin in the cytoplasmic or perinuclear region
of epithelial cells in papillary serous ovarian carcinoma
and endometrioid adenocarcinoma. Strong prohibitin
immunoreactivity has been observed in these ovarian
tumor cells. Moreover, prohibitin protein content corre-
lates well with that of XIAP in these ovarian tumors and
its level is higher than normal ovarian epithelium sam-
ples. The specific roles of prohibitin in ovarian cancer cell
differentiation and mitochondrial metabolism await fur-
ther investigation. However, it is possible that prohibitin
may be important in the maintenance of mitochondrial
integrity and that a loss of function might result in meta-
bolic defects or apoptosis [70]. Finally, the observation
that prohibitin translocates to the nucleus suggests it
might also have a role in regulating cell cycle progression.
Cross-talk of Cell Survival and Death Pathways 
in Chemoresistance
While each of the aforementioned pathways may influ-
ence cell fate on its own, the cell must ultimately respond
to a given stimuli (e.g. a chemotherapeutic agent) to either
live or die. Thus, cross-talk between cell survival and cell
death pathways ensures the cell receives an integrated sig-
nal which ultimately determines the fate of the cells (i.e.
survival or death). This latter aspect has resulted in
research activities that have significantly increased our
current understanding of not only cell death/survival reg-
ulation, but also the molecular mechanisms of chemore-
sistance. Some of these activities are summarized
hereafter.
Modulation of Death Receptor Signaling: Role of 
Xiap
Recent studies have demonstrated that Xiap may play a
role in the control of both receptor-mediated cell survival
and death signaling by directly inhibiting the principle
effectors of apoptosis, downstream caspases [11,51]. Xiap
plays a central role in promoting cell survival by inhibit-
ing caspase-3 and -7 directly and modulating the Bax/
cytochrome c pathway by inhibiting caspase-9. Structure-
function analysis of Xiap has revealed that the region of
Xiap containing the second BIR domain is necessary for
inhibiting caspase-3 and -7 whereas the third BIR domain
of Xiap is responsible for the inhibition of caspase-9
[71,72]. Xiap down-regulation following adenoviral Xiap
antisense expression in ovarian cancer cell lines has been
associated with onset of apoptosis, sensitization of chem-
oresistant cells to cisplatin, and detectable cleavage of cas-
pase-3 [19,73]. In addition, Fas activation following FasL
binding leads to initiation of the apoptotic process, which
involves the activation of caspase-8 and caspase-3. By
inhibiting caspase-3, Xiap attenuates Fas-mediated death
signaling, which appears to be important in cisplatin-
mediated apoptosis [7] (Figure 2).
The inability of TNFα to induce apoptosis upon binding
to TNFR1 has been correlated to the induction of survival
factors such as Xiap and FLIP [74,75]. Xiap does not
appear to be an important determinant of resistance to the
cytotoxic actions of the cytokine, as Xiap content in these
cells is decreased by TNFα. We have shown that, in the
presence of CHX, TNFα induces Xiap cleavage in these
cancer cells [30]. Deveraux et al have shown that cleavage
of Xiap results in different fragments with different specif-
icity for caspases and even though the BIR2 domain of
XIAP is required and sometimes sufficient for inhibition
of caspase-3, the cleaved BIR2 fragment has reduced abil-
ity to inhibit caspase-3 and to suppress apoptosis [76].
These findings support the hypothesis that caspase-3-
mediated processing of Xiap may somehow be involved
in the execution of apoptosis in response to TNFα in ovar-
ian cancer cells.
Previous studies have shown that sensitivity of melanoma
cells to TRAIL-induced apoptosis is determined by level of
expression of death receptor, TRAIL-R2 [77]. More impor-
tantly, there is a correlation between expression of this
receptor and levels of activated caspase-3 in melanoma
cells. However, despite high TRAIL-R2 expression and
TRAIL-activated caspase-3 level, some melanoma cells
were resistant to TRAIL-induced apoptosis. Inhibition of
TRAIL-induced apoptosis by Xiap is the most possible
explanation since over-expression of Xiap in TRAIL sensi-
tive cell lines markedly suppressed TRAIL induced apop-
tosis whereas over-expression of Smac/DIABLO in TRAIL
resistant melanoma cell lines sensitized the cells to TRAIL-
induced apoptosis [77]. These results are consistent with
the notion that Xiap suppresses TRAIL-induced apoptosis
in these cells. Whether Xiap plays a similar role in the reg-
ulation of TRAIL-induced apoptosis, and thus the resist-
ance of ovarian cancer cells to TRAIL, needs to be
determined.
Modulation of Death Receptor Signaling: Role of 
FLIP
TNF-α, FasL and TRAIL are members of a growing family
of cytokines which are cytotoxic to certain cancer cellsReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66
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[21]. The sensitivity of cancer cells to cytokine-induced
apoptosis is subject to complex regulatory processes,
including the cell surface receptors and antiapoptotic
proteins, such as FLIP, which can interfere with cytokine-
mediated death pathways. TNFα is believed to play an
important role in ovarian cancer biology and tumorigen-
esis, with concentrations significantly increased in ovarian
cancer patients [78] and levels of TNFα expression posi-
tively correlated with tumor grade [79].
Our recent findings indicate that FLIPs plays a key role in
conferring cellular resistance to the cytotoxic actions of
TNFα in human ovarian cancer cells. While TNFα alone
was unable to induce apoptosis, it effectively induced cas-
pase-8 and -3 cleavage as well as apoptotic cell death
when FLIP was downregulated by antisense expression
[30]. Furthermore, up-regulation of FLIPs by FLIPs sense
cDNA attenuated TNFα-induced cell death in the presence
of the protein synthesis inhibitor cycloheximide [30]. In
addition, challenge of ovarian cancer cells with TNFα
resulted in a rapid increase in phosphorylated IκB con-
tent, which was temporally associated with NFκB translo-
cation to the nucleus, and increased nuclear NFκB-
binding activity and the expression of FLIPs but not of
FLIPL, all responses readily attenuated by dominant nega-
tive IκB. Our data also demonstrated that in the presence
of CHX, TNFα induces Xiap cleavage in an ovarian cancer
cell line, a process sensitive to the caspase inhibitors
ZVAD and DEVD [30]. These findings are consistent with
recent evidence showing that TNFα-induced FLIPs expres-
sion is mediated through activation of the NFκB signaling
pathway and that FLIPs expression is an important deter-
minant of resistance of human epithelial tumor cells to
TNFα (Figure 2) [30,75,80,81]. They also support the con-
tention that a caspase-3-mediated decrease in XIAP con-
tent may be involved in the execution of apoptosis in
ovarian cancer cells in response to TNFα.
Xiap and FAK in Chemoresistance
As mentioned earlier, overexpression of FAK appears to
promote the activation of NFκB and to enhance the
expression of Xiap. Interestingly, FAK contains a consen-
sus D-X-X-D caspase-3 cleavage site at amino acid 772.
While caspase-3-mediated cleavage of FAK has been
demonstrated in several studies, the exact consequences of
this event are unclear. Cleavage of FAK at this site results
in the separation of the C-terminal Focal Adhesion Target-
ing (FAT) sequence from the kinase domain. It is possible
that this cleaved FAK may be ineffective in transmitting
survival signals, or may actively promote cell cycle arrest
and/or apoptosis [54].
We have recently investigated the role of FAK in cisplatin-
mediated apoptosis in ovarian cancer cells [51]. Cisplatin
induced FAK cleavage in a dose- and time-dependent
manner in cultured cells. However, only those cells that
detached from the culture surface following cisplatin chal-
lenge showed FAK cleavage. Moreover, the observed pat-
tern of cisplatin-induced FAK cleavage could be
recapitulated by the addition of recombinant active cas-
pase-3 to whole-cell lysates. Overexpression of Xiap pre-
vented cisplatin-mediated cleavage of FAK and rendered
the cell resistant to the pro-apoptotic effects of the drug.
These effects were dependent upon the presence of Xiap's
BIR domains, suggesting that inhibition of caspases is an
important determinant of Xiap-mediated protection of
FAK and of cell viability. Finally, pharmacological inhibi-
tors of caspase-3 could likewise inhibit cisplatin-induced
cell detachment and FAK cleavage. Taken together, these
results suggest that cisplatin-mediated apoptosis in ovar-
ian cancer cells may involve cleavage of FAK, with subse-
quent disruption of cell adhesion. Since Xiap inhibits
these processes and is a determinant of chemosensitivity
in these cells, it is possible that Xiap-mediated chemore-
sistance may, in part, be due to maintenance of FAK integ-
rity following cisplatin challenge (Figure 2).
A Central Role of p53 in Xiap- and Akt-mediated 
Chemoresistance
Although Xiap and the PI3K/Akt pathway are important
cell survival factors, if and how they interact in the induc-
tion and maintenance of chemoresistance in human ovar-
ian cancer is not known. We previously reported that
cisplatin down-regulates Xiap in ovarian cancer cells
which are chemosensitive but not chemoresistant [8].
Moreover, Xiap is a determinant of chemoresistance, since
downregulation of Xiap in chemoresistant cells rendered
the cells sensitive to the cytotoxic actions of cisplatin,
while overexpression of Xiap in chemosensitive cells
caused a reversion to the chemoresistant phenotype
[8,19].
Several studies have linked the PI3K/Akt pathway to
chemoresistance in ovarian cancer. Our laboratory has
been particularly interested in the potential interactions
between Xiap and the PI3K/Akt pathway. We have dem-
onstrated that treatment of chemosensitive ovarian cancer
cells with cisplatin decreases Xiap content, activates cas-
pase-3 and -9, and induces Akt cleavage and apoptosis.
However, these phenomenon are not observed in the
chemoresistant counterpart [8,73]. Moreover, the ability
of cisplatin to downregulate Xiap, and to induce Akt cleav-
age and apoptosis was attenuated by pretreatment with a
cell-permeable caspase-3 inhibitor. These findings suggest
that cisplatin-mediated apoptosis is dependent on cas-
pase-3 activation, and involves modulation of the Akt cell
survival pathway.
While failure of cisplatin to down-regulate Xiap is a hall-
mark of chemoresistance and Xiap overexpression inReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66
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chemosensitive ovarian cancer cells renders the cells
resistant to cisplatin, the mechanistic underpinning for
these phenomena is unclear. While several studies have
established the inhibitory role of Xiap on caspase 3, 7 and
9, recent work has linked Xiap to a number of other sign-
aling pathways, including the TGF-β/BMP and JNK path-
ways [82–85]. In addition, we have previously observed a
co-localization between Xiap and phospho-Akt in human
ovarian tumor sections and in nude mouse ovarian cancer
xenografts (unpublished observations). Furthermore,
Xiap and phospho-Akt staining was inversely correlated
with apoptosis, as assayed by TUNEL staining. These pre-
liminary findings suggest that there may be some relation-
ship between Xiap and Akt, and intriguingly, that
chemoresistance conferred by these cell survival interme-
diates may be related. Our recent work has demonstrated
that Xiap overexpression in chemosensitive cells increases
phospho-Akt content and attenuates cisplatin-induced
apoptosis [73]. Total Akt (phosphorylated + non-phos-
phorylated) was not altered by Xiap, nor was the expres-
sion of the p85 subunit of PI3K, suggesting a direct
influence of Xiap upon Akt activation rather than an up-
regulation of Akt expression. Furthermore, Xiap-mediated
chemoresistance could be attenuated by either the PI3K
inhibitor LY294002 [73] or an adenoviral dominant-neg-
ative Akt [49], suggesting that activation of Akt is an
important determinant of Xiap-mediated chemoresist-
ance. Interestingly, our very recent results suggest that
while cisplatin decreases Xiap content and induces apop-
tosis in chemosensitive ovarian cancer cells, the expres-
sion of a constitutively active Akt2 blocks both of these
phenomena. Moreover, while cisplatin fails to down-reg-
ulate Xiap or induce apoptosis in chemoresistant cells, the
expression of a dominant-negative Akt sensitizes cells to
these effects of the chemotherapeutic agent. These results
are significant because they suggest a feedback regulation
of Xiap and Akt. While Xiap up-regulates Akt phosphor-
ylation and requires Akt for its function, Akt protects Xiap
from downregulation by cisplatin. Thus, it appears that
there is an intricate, coordinated regulatory system at play
between Xiap and the PI3K/Akt pathway, the end result of
which leads to resistance to pharmacological doses of
cisplatin.
In addition, we have been particularly interested in the
possibility that aberrant regulation of the p53 tumor sup-
pressor may be an important determinant of chemoresist-
ance. TP53 is a frequently mutated gene in malignant cells
[4]. Its gene product (p53), a DNA-binding protein, func-
tions as a sequence-specific transcription factor and is
post-translationally modified by phosphorylation and
ubiquitination [86]. p53 is usually sequestered in the
cytoplasm as a complex with a p53-responsive gene prod-
uct, Murine Double Minute-2 (MDM2), which limits its
transactivational capacity. Moreover, MDM2 is a E3 ubiq-
uitin ligase for p53, thus facilitating the degradation of
p53 via the 26S proteasome [87].
When DNA is damaged, several upstream kinases in the
cells, including ATM, ATR and MAP kinases (ERK, JNK,
and p38), phosphorylate p53 on its N-terminal near the
MDM2-binding site [88], thus decreasing the affinity of
MDM2 for p53 and resulting in decreased ubiquitination
and increased transactivational activity of p53. Free p53
enters the nucleus and binds to specific DNA sequences,
either repressing or stimulating the expression of target
genes. The role of p53 on cell fate following DNA damage
depends on the duration and severity of the damage [89].
Short duration or less severe damage often results in the
expression of proteins involved in cell cycle arrest and
DNA repair, such as p21WAF1/CIP1 and  GADD45. p21 is
required for p53-mediated suspension of the cell cycle at
the G1 phase, while GADD45 is involved in DNA repair
[90]. However, prolonged or severe DNA damage leads
the upregulation of p53-responsive genes (e.g. Bax, Fas)
and the induction of apoptosis through the mitochon-
drial death pathway [91]. Death receptor mediated apop-
tosis is also achieved by p53-mediated upregulation of Fas
[90].
During apoptosis, MDM2 is cleaved, permitting the accu-
mulation of p53 and thus the promotion of the apoptotic
response. Xiap downregulation is associated with MDM2
cleavage, p53 stabilization and accumulation, and apop-
tosis in chemoresistant p53 wild-type ovarian cancer cells
[19]. However, these phenomena are not observed in a
chemoresistant p53 mutant cell line, unless wild-type p53
is first reconstituted, suggesting that p53 status may be an
important determinant of Xiap-mediated chemoresist-
ance. In addition, our recent studies demonstrate that
while downregulation of Akt activity in p53 wild-type,
chemoresistant ovarian cancer cells renders the cells sensi-
tive to cisplatin, this effect is not observed in p53 mutant,
chemoresistant cells. Again, the phenomenon is restored
by expression of exogenous wild-type p53. Addition of the
specific p53 inhibitor Pifithrin-α-hydrobromide (PFT) to
ovarian cancer cell culture reverses the dominant-negative
Akt-mediated sensitization of the chemoresistant, p53
wild-type cells, and the chemoresistant p53 mutant in
which wild-type p53 was reconstituted [49].
Cisplatin up-regulates p53 in a number of systems [6,92].
However, the precise mechanisms that give rise to this
phenomemon are not clear. We have recently demon-
strated that while cisplatin increases p53 content in chem-
osensitive, p53 wild-type ovarian cancer cells, it fails to do
so in a chemoresistant, p53 wild-type variant [49]. How-
ever, cisplatin is capable of upregulating p53 and induc-
ing apoptosis in these cells following expression of
dominant-negative Akt, suggesting that the cisplatin-Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66
Page 10 of 13
(page number not for citation purposes)
mediated upregulation of p53 is opposed by Akt. Interest-
ingly, MDM2 has been shown to be a target of phosphor-
ylation by Akt [93–96]. These studies have established
that phosphorylation by Akt activates MDM2, thereby
maintaining p53 levels low. However, whether this proc-
ess contributes to the failure to upregulate p53 following
cisplatin challenge in chemoresistant cells is not known.
Taken together, these results suggest that p53 status is an
important determinant of Xiap- and Akt-mediated chem-
oresistance (Figure 2).
Interaction of Prohibitin with Retinoblastoma 
(Rb) Protein
The prohibitin gene is a potential tumor suppressor that
has been linked to human cancer. Sato et al (1992, 1993)
identified four mutations in 23 sporadic breast cancer
patients and provided the first evidence for the tumor sup-
pressive nature of prohibitin in breast cancer tumorigene-
sis [65,97]. More recently, Jupe et al. (2001) identified
two prohibitin alleles that correlate with the predisposi-
tion to breast cancer tumorigenesis in a clinical study
involving 205 patients [98]. Although the RNA encoding
the 3' UTR of the prohibitin gene has been reported to
suppress cell proliferation by blocking G1/S transition of
the cell cycle [99], the mechanism by which this occurs is
unclear. The Rb gene was the first tumor suppressor to be
cloned, but the mechanism behind its role in tumor sup-
pression remains unclear. Accumulating evidence indi-
cates a complex role for Rb in cell proliferation,
differentiation and survival. The retinoblastoma gene was
initially identified as a genetic locus associated with the
development of an inherited eye tumor [100,101]. The
realization that it was a loss of function of Rb that was
associated with disease established the tumor suppressor
paradigm [102]. Subsequent work identified the E2F tran-
scription factor activity as a key target for the growth sup-
pressing action of the Rb protein [103]. Additional studies
demonstrated that Rb function requires interaction with
E2F and phosphorylation; a mechanism that is mediated
by D-type cyclin-dependent kinases [104–106]. D cyclin/
cdk4 activity is induced by growth stimulation, thus initi-
ating the cascade of events that leads to E2F accumulation
and S-phase entry [107]. Wang et al. reported that
prohibitin physically interacts with Retinoblastoma (Rb)
protein and regulates E2F function, a response correlated
with its growth suppressive activity [108,109] (Figure 2).
Although the molecular mechanism by which prohibitin-
mediated E2F repression is not fully understood, the
recruitment of the histone deacetylase HDAC1 for tran-
scriptional repression of the E2F family and the involve-
ment of co-repressors such as NcoR appears necessary
[98]. Evidence also exists that prohibitin can also act inde-
pendently of Rb. Some E2F-responsive promoters appear
to be unaffected by the recruitment of HDAC [110], sug-
gesting alternative mechanisms involving other transcrip-
tional repressors (e.g. Brg-1 and Brm) may be involved
[111–113]. In this context, Wang et al (2002) demon-
strated that prohibitin requires Brg-1 and Brm for tran-
scription repression of E2F-1 [114]. The recruitment of
Brg-1 and Brm by prohibitin is independent of Rb, while
the transcriptional repression mediated by prohibitin/
Brg-1/Brm requires Rb, and is reconstituted when Rb is co-
transfected in Rb-deficient cells. Whether similar regula-
tory mechanisms involving prohibitin exist in the ovary is
currently under investigation.
Conclusions and Future Directions
Chemoresistance is a therapeutic problem that severely
limits successful treatment outcomes for many human
cancers. This is particularly true of ovarian cancer, where
the development of resistance is a common occurrence.
The past few years have seen an enormous growth in our
understanding of the mechanisms that regulate drug-
induced apoptosis, and thus influence chemosensitivity.
However, it is important to remember that no biochemi-
cal pathway stands on its' own. While these pathways
have previously been considered disparate, recent studies
have shown complex interactions between them in cell
fate regulation. Xiap, for example, was originally charac-
terized according to its' ability to inhibit caspases. How-
ever, recent data suggests that this anti-apoptotic protein
interacts with a number of fundamental cell survival path-
ways, such as the PI3K/Akt pathway. Similarly, the p53
tumor suppressor, while critically important in the medi-
ation of apoptosis triggered by chemotherapeutic agents,
has now been shown to be itself regulated by anti-apop-
totic proteins such as MDM2 and Akt. Ultimately, the suc-
cess of chemotherapy depends on our understanding of
the integration of these pathways, with the issuance of a
proper life or death signal. While the recent discovery of
these biochemical interactions is intriguing, it must be
noted that our understanding of the precise mechanisms
by which these interactions occur is incomplete. For
instance, while Akt appears to attenuate the effects of cis-
platin on p53 (i.e. upregulation) and on Xiap (i.e. down-
regulation), the mechanisms involved are unclear. One
intriguing possibility is that specific post-translational
modifications critical for the response to cisplatin may be
altered in chemoresistant cells. For instance, under spe-
cific cellular conditions, both p53 and Xiap are ubiquiti-
nated and degraded in the 26S proteasome. It is possible,
therefore, that Akt may be influencing the stability of
either or both of these proteins via altered ubiquitination
pathways. These types of specific mechanistic questions
will drive the future of research in this area. In addition,
the development of advanced molecular techniques will
be crucial for the success of this endeavour. The next few
years will likely be critical in determining the precise
mechanisms controlling the onset and maintenance ofReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66
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chemoresistance, and will likely suggest several new meth-
ods for overcoming this enormous clinical problem.
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